Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Regional Nodal Irradiation in the Modern Era of Breast Cancer Management.

Belkacemi Y, Smith BD, Horton JK.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):241-243. doi: 10.1016/j.ijrobp.2017.10.036. No abstract available.

PMID:
29726346
2.

Treatment constraints for single dose external beam preoperative partial breast irradiation in early-stage breast cancer.

Charaghvandi RK, Yoo S, van Asselen B, Rodrigues A, van den Bongard DHJG, Horton JK.

Clin Transl Radiat Oncol. 2017 Sep 8;6:7-14. doi: 10.1016/j.ctro.2017.06.003. eCollection 2017 Oct.

3.

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2018 May 1;36(13):1317-1322. doi: 10.1200/JCO.2017.77.2665. Epub 2018 Mar 20.

PMID:
29558281
4.

XRCC1 phosphorylation affects aprataxin recruitment and DNA deadenylation activity.

Horton JK, Stefanick DF, Çağlayan M, Zhao ML, Janoshazi AK, Prasad R, Gassman NR, Wilson SH.

DNA Repair (Amst). 2018 Apr;64:26-33. doi: 10.1016/j.dnarep.2018.02.004. Epub 2018 Feb 15.

PMID:
29477978
5.

Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy.

Horton JK, Jagsi R, Woodward WA, Ho A.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):23-37. doi: 10.1016/j.ijrobp.2017.08.025. Review.

PMID:
29254776
6.

How Low Can We Go-and Should We? Risk Reduction for Minimal-Volume DCIS.

Ryser MD, Horton JK, Hwang ES.

Ann Surg Oncol. 2018 Feb;25(2):354-355. doi: 10.1245/s10434-017-6128-4. Epub 2017 Nov 13. No abstract available.

PMID:
29134379
7.

DNA polymerase β: A missing link of the base excision repair machinery in mammalian mitochondria.

Prasad R, Çağlayan M, Dai DP, Nadalutti CA, Zhao ML, Gassman NR, Janoshazi AK, Stefanick DF, Horton JK, Krasich R, Longley MJ, Copeland WC, Griffith JD, Wilson SH.

DNA Repair (Amst). 2017 Dec;60:77-88. doi: 10.1016/j.dnarep.2017.10.011. Epub 2017 Oct 28.

PMID:
29100041
8.

XRCC1-mediated repair of strand breaks independent of PNKP binding.

Horton JK, Stefanick DF, Zhao ML, Janoshazi AK, Gassman NR, Seddon HJ, Wilson SH.

DNA Repair (Amst). 2017 Dec;60:52-63. doi: 10.1016/j.dnarep.2017.10.007. Epub 2017 Oct 19.

PMID:
29100039
9.

Postmastectomy Conundrum.

Horton JK.

Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):976. doi: 10.1016/j.ijrobp.2017.04.013. Epub 2017 Apr 19. No abstract available.

PMID:
28721909
10.

Subtype-Specific Radiation Response and Therapeutic Effect of FAS Death Receptor Modulation in Human Breast Cancer.

Lee CT, Zhou Y, Roy-Choudhury K, Siamakpour-Reihani S, Young K, Hoang P, Kirkpatrick JP, Chi JA, Dewhirst MW, Horton JK.

Radiat Res. 2017 Aug;188(2):169-180. doi: 10.1667/RR14664.1. Epub 2017 Jun 9.

PMID:
28598289
11.

Role of the oxidized form of XRCC1 in protection against extreme oxidative stress.

Horton JK, Seddon HJ, Zhao ML, Gassman NR, Janoshazi AK, Stefanick DF, Wilson SH.

Free Radic Biol Med. 2017 Jun;107:292-300. doi: 10.1016/j.freeradbiomed.2017.02.005. Epub 2017 Feb 4.

12.

Oxidized nucleotide insertion by pol β confounds ligation during base excision repair.

Çağlayan M, Horton JK, Dai DP, Stefanick DF, Wilson SH.

Nat Commun. 2017 Jan 9;8:14045. doi: 10.1038/ncomms14045.

13.

DNA polymerase β contains a functional nuclear localization signal at its N-terminus.

Kirby TW, Gassman NR, Smith CE, Zhao ML, Horton JK, Wilson SH, London RE.

Nucleic Acids Res. 2017 Feb 28;45(4):1958-1970. doi: 10.1093/nar/gkw1257.

14.

FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target.

Horton JK, Siamakpour-Reihani S, Lee CT, Zhou Y, Chen W, Geradts J, Fels DR, Hoang P, Ashcraft KA, Groth J, Kung HN, Dewhirst MW, Chi JT.

Radiat Res. 2015 Nov;184(5):456-69. doi: 10.1667/RR14089.1. Epub 2015 Oct 21.

15.

Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.

Siamakpour-Reihani S, Owzar K, Jiang C, Turner T, Deng Y, Bean SM, Horton JK, Berchuck A, Marks JR, Dewhirst MW, Alvarez Secord A.

Gynecol Oncol. 2015 Oct;139(1):23-9. doi: 10.1016/j.ygyno.2015.08.001. Epub 2015 Aug 7.

16.
17.

Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers.

Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, Duffy EA, Chi JT, Hwang ES.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):846-55. doi: 10.1016/j.ijrobp.2015.03.007. Epub 2015 Mar 14.

18.

A phase 1 trial of preoperative partial breast radiation therapy: Patient selection, target delineation, and dose delivery.

Blitzblau RC, Arya R, Yoo S, Baker JA, Chang Z, Palta M, Duffy E, Horton JK.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e513-e520. doi: 10.1016/j.prro.2015.02.002. Epub 2015 Mar 31.

19.

Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.

Siamakpour-Reihani S, Owzar K, Jiang C, Scarbrough PM, Craciunescu OI, Horton JK, Dressman HK, Blackwell KL, Dewhirst MW.

Int J Hyperthermia. 2015 Jun;31(4):386-95. doi: 10.3109/02656736.2015.1016557. Epub 2015 Mar 26.

20.

Exercise behavior and patient-reported outcomes in women with early breast cancer receiving locoregional radiation therapy.

Arya R, Siamakpour-Reihani S, Palta M, Massa L, Broadwater G, Blitzblau RC, Horton JK.

Pract Radiat Oncol. 2015 Jul-Aug;5(4):e275-81. doi: 10.1016/j.prro.2015.01.003. Epub 2015 Feb 26.

PMID:
25731964
21.

Bisphenol a promotes cell survival following oxidative DNA damage in mouse fibroblasts.

Gassman NR, Coskun E, Stefanick DF, Horton JK, Jaruga P, Dizdaroglu M, Wilson SH.

PLoS One. 2015 Feb 18;10(2):e0118819. doi: 10.1371/journal.pone.0118819. eCollection 2015.

22.

Dosimetric comparison of preoperative single-fraction partial breast radiotherapy techniques: 3D CRT, noncoplanar IMRT, coplanar IMRT, and VMAT.

Yoo S, Blitzblau R, Yin FF, Horton JK.

J Appl Clin Med Phys. 2015 Jan 8;16(1):5126. doi: 10.1120/jacmp.v16i1.5126.

23.

Complementation of aprataxin deficiency by base excision repair enzymes.

Çağlayan M, Horton JK, Prasad R, Wilson SH.

Nucleic Acids Res. 2015 Feb 27;43(4):2271-81. doi: 10.1093/nar/gkv079. Epub 2015 Feb 6.

24.

Oncology scan--quality of life and patient perspectives during breast radiation therapy.

Horton JK, Bellon JR.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):249-51. doi: 10.1016/j.ijrobp.2014.08.007. No abstract available.

PMID:
25636750
25.

Enzymatic Activity Assays for Base Excision Repair Enzymes in Cell Extracts from Vertebrate Cells.

Çağlayan M, Horton JK, Wilson SH.

Bio Protoc. 2015;5(11). pii: e1493. Epub 2015 Jun 5.

26.

DNA polymerase β-dependent cell survival independent of XRCC1 expression.

Horton JK, Gassman NR, Dunigan BD, Stefanick DF, Wilson SH.

DNA Repair (Amst). 2015 Feb;26:23-9. doi: 10.1016/j.dnarep.2014.11.008. Epub 2014 Dec 3.

27.

The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343.

Palta M, Palta P, Bhavsar NA, Horton JK, Blitzblau RC.

Cancer. 2015 Jan 15;121(2):188-93. doi: 10.1002/cncr.28937. Epub 2014 Dec 8.

28.

Performance testing of a semi-automatic card punch system, using direct STR profiling of DNA from blood samples on FTA™ cards.

Ogden SJ, Horton JK, Stubbs SL, Tatnell PJ.

J Forensic Sci. 2015 Jan;60 Suppl 1:S207-12. doi: 10.1111/1556-4029.12622. Epub 2014 Nov 18.

PMID:
25407399
29.

Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.

McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF.

Ann Surg Oncol. 2015 Jan;22(1):75-81. doi: 10.1245/s10434-014-3948-3. Epub 2014 Jul 25.

30.

Suicidal cross-linking of PARP-1 to AP site intermediates in cells undergoing base excision repair.

Prasad R, Horton JK, Chastain PD 2nd, Gassman NR, Freudenthal BD, Hou EW, Wilson SH.

Nucleic Acids Res. 2014 Jun;42(10):6337-51. doi: 10.1093/nar/gku288. Epub 2014 Apr 25.

31.

Base excision repair defects invoke hypersensitivity to PARP inhibition.

Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH.

Mol Cancer Res. 2014 Aug;12(8):1128-39. doi: 10.1158/1541-7786.MCR-13-0502. Epub 2014 Apr 25.

32.

Treatment planning technique in patients receiving postmastectomy radiation therapy.

Blitzblau RC, Horton JK.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):241-8. doi: 10.1016/j.prro.2012.09.004. Epub 2012 Dec 4. Review.

PMID:
24674393
33.

Dosimetric comparison of 3D conformal, IMRT, and V-MAT techniques for accelerated partial-breast irradiation (APBI).

Qiu JJ, Chang Z, Horton JK, Wu QR, Yoo S, Yin FF.

Med Dosim. 2014 Summer;39(2):152-8. doi: 10.1016/j.meddos.2013.12.001. Epub 2014 Jan 27.

PMID:
24480375
34.

Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity.

Horton JK, Wilson SH.

Front Oncol. 2013 Sep 30;3:257. doi: 10.3389/fonc.2013.00257. Review.

35.

Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses.

Horton JK, Stefanick DF, Gassman NR, Williams JG, Gabel SA, Cuneo MJ, Prasad R, Kedar PS, Derose EF, Hou EW, London RE, Wilson SH.

DNA Repair (Amst). 2013 Sep;12(9):774-85. doi: 10.1016/j.dnarep.2013.06.004. Epub 2013 Jul 18.

36.

Interaction between DNA Polymerase β and BRCA1.

Masaoka A, Gassman NR, Horton JK, Kedar PS, Witt KL, Hobbs CA, Kissling GE, Tano K, Asagoshi K, Wilson SH.

PLoS One. 2013 Jun 27;8(6):e66801. doi: 10.1371/journal.pone.0066801. Print 2013.

37.

Radiotherapy after mastectomy.

Blitzblau RC, Horton JK.

Surg Oncol Clin N Am. 2013 Jul;22(3):563-77. doi: 10.1016/j.soc.2013.02.012. Epub 2013 Mar 19. Review.

PMID:
23622080
38.

Oncology scan--breast cancers.

Horton JK, Jagsi R.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1151-2. doi: 10.1016/j.ijrobp.2013.01.007. No abstract available.

PMID:
23523000
39.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

40.

Predicting enhanced cell killing through PARP inhibition.

Horton JK, Wilson SH.

Mol Cancer Res. 2013 Jan;11(1):13-8. doi: 10.1158/1541-7786.MCR-12-0512. Epub 2012 Nov 27.

41.

Hyperactivation of PARP triggers nonhomologous end-joining in repair-deficient mouse fibroblasts.

Gassman NR, Stefanick DF, Kedar PS, Horton JK, Wilson SH.

PLoS One. 2012;7(11):e49301. doi: 10.1371/journal.pone.0049301. Epub 2012 Nov 7.

42.

Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

Kimple RJ, Horton JK, Livasy CA, Shields JM, Lawrence JA, Chiu WM, Ivanova A, Ollila DW, Carey LA, Halle JS, Sartor CI, Dees EC.

Oncologist. 2012;17(12):1496-503. doi: 10.1634/theoncologist.2012-0256. Epub 2012 Sep 24.

43.

Risk of invasive breast cancer and ductal carcinoma in situ in women with atypical papillary lesions of the breast.

Cuneo KC, Dash RC, Wilke LG, Horton JK, Koontz BF.

Breast J. 2012 Sep;18(5):475-8. doi: 10.1111/j.1524-4741.2012.01276.x. Epub 2012 Jul 10.

PMID:
22776070
44.

HMGN1 protein regulates poly(ADP-ribose) polymerase-1 (PARP-1) self-PARylation in mouse fibroblasts.

Masaoka A, Gassman NR, Kedar PS, Prasad R, Hou EW, Horton JK, Bustin M, Wilson SH.

J Biol Chem. 2012 Aug 10;287(33):27648-58. doi: 10.1074/jbc.M112.370759. Epub 2012 Jun 26.

45.

Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.

Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL.

Br J Cancer. 2012 Feb 28;106(5):916-22. doi: 10.1038/bjc.2012.32. Epub 2012 Feb 14.

46.

Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.

Kedar PS, Stefanick DF, Horton JK, Wilson SH.

Mol Cancer Res. 2012 Mar;10(3):360-8. doi: 10.1158/1541-7786.MCR-11-0477. Epub 2012 Jan 13.

47.

A comparison of clinical and dosimetric outcomes in patients receiving partial breast irradiation with photon-only versus mixed photon/electron treatment plans.

Shah MM, Horton JK, Yoo S, Hubbs JL, Demirci S, Light KL, Temple K, Patrone M, Marks LB.

Med Dosim. 2011 Winter;36(4):423-8. doi: 10.1016/j.meddos.2010.10.004. Epub 2011 Mar 26.

PMID:
21440433
48.

Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma.

Horton JK, Gleason JF Jr, Klepin HD, Isom S, Fried DB, Geiger AM.

Cancer. 2011 Sep 1;117(17):4033-40. doi: 10.1002/cncr.25996. Epub 2011 Mar 8.

49.

Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibition.

Horton JK, Stefanick DF, Zeng JY, Carrozza MJ, Wilson SH.

DNA Repair (Amst). 2011 Feb 7;10(2):225-34. doi: 10.1016/j.dnarep.2010.11.003. Epub 2010 Dec 3.

50.

Lessons learned: Staff perceptions of the Nintendo Wii as a health promotion tool within an aged-care and disability service.

Higgins HC, Horton JK, Hodgkinson BC, Muggleton SB.

Health Promot J Austr. 2010 Dec;21(3):189-95.

PMID:
21118065

Supplemental Content

Loading ...
Support Center